CatSci acquires chromatography provider Reach Separations


CatSci has acquired Reach Separations, a specialist chromatography provider for the analysis and purification of therapeutics.

The acquisition was supported by Keensight Capital, private equity managers dedicated to pan-European Growth Buyout investments.

Headquartered in the UK, and with laboratories in both the UK and France, Reach Separations specialises in chromatography for the analysis and purification of chiral and achiral therapeutics.

Reach assists in delivering purification projects from discovery chromatography through to large scale Supercritical Fluid Chromatography (SFC) for chiral purification and impurity isolation.

The acquisition of Reach will enable CatSci to offer its global customers access to holistic chromatographic services for small molecules, oligonucleotides and other complex synthetic medicines.

Dr Ross Burn, CEO at CatSci, commented: “The need for solving complex analytical problems while meeting the ever-evolving regulatory demands is growing alongside the development of new modalities, such as oligonucleotides, targeting chimeras (TACs), and glues. Joining forces with Reach gives our customers access to end-to-end coverage of the analytical development lifecycle, taking them from discovery through to GMP manufacture, and ultimately enabling them to help patients in need.”

Peter Ridgway, Business Development Director at Reach Separations, added: “Integrating our technologies and expertise across the discovery and development landscape will provide a one-stop- shop for analysis and purification, giving the client a variety of options to progress the journey of their asset.”

The acquisition is effective immediately, and the companies say they will work closely to ensure a seamless transition for customers and stakeholders.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free